Denmark’s Zealand Pharma has announced changes to its company’s organization and management structures.
The research and development organization has been split into two parts, each with direct representation in management. In addition, investor relations & communications also will be represented directly at management level.
The reorganization eliminates one management level to help streamline operations and decision- making. Research to support and sustain Zealand’s work creating new peptide medicines will receive greater emphasis. “At the same time, the new structure will ensure optimal focus on value creation through increased investment in the clinical development of Zealand’s wholly-owned products,” according to a company statement.
The company is eliminating the chief scientific officer and chief operating officer positions.
Adam Steensberg, Vice President for Development, has been promoted and appointed to the new position of Senior Vice President for Development and Chief Medical Officer. The new position of Senior Vice President for Research will be filled temporarily by Keld Fosgerau, Vice President for Research, while the company searches for a permanent appointment. Hanne Leth Hillman, Vice President for Investor Relations and Corporate Communications has been promoted and appointed to the new position of Senior Vice President for Investor Relations & Communications.